"Texas Oncology is an independent private practice with more than 500 physicians and 210 locations across the state. Meeting the oncology needs of Texans for more than 35 years, the practice includes Texas Center for Proton Therapy, Texas Breast Specialists, Texas Oncology Surgical Specialists, and Texas Center for Interventional Surgery. As a lead participant in US Oncology Research, Texas Oncology played a role in the development of more than 100 FDA-approved therapies."

During the past decade, Texas Oncology- San Marcos conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 8 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 5 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Texas Oncology- San Marcos" #1 collaborator was "National Cancer Institute (NCI)" with 3 trials as a collaborator, "Cancer and Leukemia Group B" with 2 trials as a collaborator, "NCIC Clinical Trials Group" with 2 trials as a collaborator, "SWOG Cancer Research Network" with 2 trials as a collaborator and "American College of Surgeons" with 1 trials as a collaborator. Other collaborators include 1 different institutions and companies that were collaborators in the rest 11 trials.

According to Clinical.Site data, the most researched conditions in "Texas Oncology- San Marcos" are "Breast Cancer" (2 trials), "Clear Cell Renal Cell Carcinoma" (2 trials), "Stage IA Breast Cancer AJCC v7" (2 trials), "Stage IB Breast Cancer AJCC v7" (2 trials) and "Stage IIA Breast Cancer AJCC v6 and v7" (2 trials). Many other conditions were trialed in "Texas Oncology- San Marcos" in a lesser frequency.

Most popular intervention types in "Texas Oncology- San Marcos" are "Drug" (9 trials), "Other" (7 trials), "Biological" (6 trials), "Radiation" (2 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (6 trials), "Bevacizumab" (3 trials), "Quality-of-Life Assessment" (3 trials), "Letrozole" (2 trials) and "Paclitaxel" (2 trials). Other intervention names were less common.

The vast majority of trials in "Texas Oncology- San Marcos" are 5 trials for "All" genders, 4 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Texas Oncology- San Marcos". undefined are not yet recruiting, undefined are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in Texas Oncology- San Marcos, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Texas Oncology- San Marcos, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".